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INTRODUCTION
Breast implants are one of the most commonly used 
medical implants in healthcare. Estimating the prevalence 
of breast implants remains a challenge; however, in a study 
from 2018, an estimated 3.3% of all women in The Neth-
erlands have a breast implant.1 A number of breast device 
clinical quality registries (CQRs) have been established 
around the world.2–4 CQRs record a minimum dataset re-
lating to surgery involving breast implants, tissue expand-
ers and additional elements such as the use of acellular 
dermal matrices and dermal meshes.
Breast device CQRs are designed to monitor the long-
term safety and performance of breast devices, track patient 
health outcomes, and benchmark the quality of surgery.5 
CQRs provide a credible means to monitor healthcare 
processes and outcomes.6 The provision of feedback of 
timely, relevant, and reliable information on patient care 
From the *Department of Epidemiology and Preventive Medicine, 
Monash University, Victoria, Australia; †Department of Plastic and 
Reconstructive Surgery, Flinders Medical Center, Flinders University, 
South Australia, Australia; ‡Westmead Breast Cancer Institute, 
Westmead Hospital, New South Wales, Australia; §Erasmus MC 
Cancer Institute, University Medical Centre Rotterdam, Rotterdam, 
The Netherlands; ¶Refine Cosmetic Clinic, New South Wales, 
Australia; ║Therapeutic Goods Administration, Australian Capital 
Territory Australia; **Macquarie Plastic & Reconstructive Surgery, 
Faculty of Medicine and Health Sciences, Macquarie University, 
New South Wales, Australia; ††Parkside Cosmetic Surgery, South 
Australia Australia; ‡‡South Island Plastic Surgery, Christchurch, 
New Zealand; §§School of Medicine, Griffith University, Queensland, 
Australia; Australasian College of Cosmetic Surgery, New South 
Wales, Australia; ║║Department of Plastic, Reconstructive and Hand 
surgery, Medisch Spectrum Twente and ZGT Almelo, Enschede, The 
Netherlands; ***School of Medicine, University of Western Australia, 
Western Australia, Australia; and †††Kliniken för Rekonstruktiv 
Plastikkirurgi Karolinska Institute, Stockholm, Sweden
Received for publication May 20, 2019; accepted May 29, 
2019.
Dr. Husna Begum and Ms. Swarna Vishwanath contributed 
equally to this work.
Background: Breast device registries monitor devices encompassing breast im-
plants, tissue expanders and dermal matrices, and the quality of care and patient 
outcomes for breast device surgery. Defining a standard set of quality indicators 
and risk adjustment factors will enable consistency and adjustment for case-mix in 
benchmarking quality of care across breast implant registries. This study aimed to 
develop a set of quality indicators to enable assessment and reporting of quality of 
care for breast device surgery which can be applied globally.
Methods: A scoping literature review was undertaken, and potential quality indicators 
were identified. Consensus on the final list of quality indicators was obtained using a 
modified Delphi approach. This process involved a series of online surveys, and tele-
conferences over 6 months. The Delphi panel included participants from various coun-
tries and representation from surgical specialty groups including breast and general 
surgeons, plastic and reconstructive surgeons, cosmetic surgeons, a breast-care nurse, 
a consumer, a devices regulator (Therapeutic Goods Administration), and a biostatisti-
cian. A total of 12 candidate indicators were proposed: Intraoperative antibiotic wash, 
intraoperative antiseptic wash, preoperative antibiotics, nipple shields, surgical plane, 
volume of implant, funnels, immediate versus delayed reconstruction, time to revision, 
reoperation due to complications, patient satisfaction, and volume of activity.
Results: Three of the 12 proposed indicators were endorsed by the panel: pre-
operative intravenous antibiotics, reoperation due to complication, and patient 
reported outcome measures.
Conclusion: The 3 endorsed quality indicator measures will enable breast device 
registries to standardize benchmarking of care internationally for patients un-
dergoing breast device surgery. (Plast Reconstr Surg Glob Open 2019;7:e2348; doi: 
10.1097/GOX.0000000000002348; Published online 19 August 2019.)
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to clinicians drives improvements in healthcare quality,7 
and benchmarking outcomes can identify variation in out-
comes to further improve healthcare quality.7,8
The International Collaboration of Breast Registry Ac-
tivities (ICOBRA) brings breast device registries together 
worldwide with the aim of monitoring the safety of breast 
devices over time and benchmarking the quality of care 
for breast device surgery.9 To achieve this, clinical quality 
indicators (QIs) for breast device surgery are needed. QIs 
measure performance and assess quality of care by exam-
ining the incidence of specific events.10 Importantly, they 
measure the quality of healthcare with little interobserver 
and intraobserver variability so that they are suitable for 
comparisons between professionals and institutions.11
QIs fall into 3 categories: structure, process, and out-
come indicators.12 Process indicators reflect what a pro-
vider does, outcome indicators reflect the impact of the 
medical care on the health status patient, and structural in-
dicators reflect the setting in which the care is delivered.13 
QIs must be both (1) valid—it must capture the quality of 
breast device surgery and (2) feasible—easy to collect.14
Risk adjustment factors (RAFs) are also important to al-
low a fair comparison across providers. Risk adjustment is 
the process of statistically accounting for differences in pa-
tient case-mix that influences healthcare outcomes.15 These 
are often patient risk factors that can be added to statistical 
models to control for their contribution to the outcome of 
interest, thus residual differences in outcomes can be attrib-
uted to provider quality once this adjustment is performed.15
Currently, there is no consensus on the appropriate 
QIs and RAFs to benchmark the quality of breast device 
surgery. We aimed to develop a set of QIs and RAFs ap-
plicable to patients undergoing both augmentation and 
reconstruction surgery with breast devices, which can be 
used by breast device registries worldwide to benchmark 
the quality of breast device surgery.
METHODS
This study was approved by the Monash University Hu-
man Research Ethics Committee.
Literature Review
Identification of QIs and RAFs
Three clinicians (N.D., E.E., M.Mur.) provided clinical 
input and identified 12 clinical questions that were consid-
ered critical to surgery utilizing breast devices. A scoping 
review of the literature on breast device surgery was done, 
articles relating to each of the clinical questions were short-
listed and used to transform the clinical questions into can-
didate QIs (refer to Table 1 for list of 12 candidate QIs). 
Articles referring to RAFs in breast device surgery were also 
identified and a list of potential RAFs was developed (refer 
to Table 2 for list of potential RAFs). All panel members 
were also given an opportunity to modify and/or suggest 
more candidate QIs or RAFs throughout the Delphi process.
Search Strategies and Data Extraction
Three databases were used (Ovid MEDLINE, EM-
BASE, and CENTRAL database), with date range 1995 
to February 2017. Review articles, gray literature includ-
ing government reports and guidelines from regulatory 
agencies were included.16 Manual reference checking 
of the bibliographies of all retrieved articles was under-
taken. All searches included keywords and correspond-
ing MeSH terms for breast implants, augmentation or 
reconstruction surgery, and study type. Studies that ad-
dressed the clinical questions were included and articles 
that did not include outcomes of breast device surger-
ies (ie, breast augmentation or reconstruction using 
devices) were excluded. Additionally, articles were ex-
cluded if the study groups involving autologous surgery, 
articles that focused solely on breast mastectomy (unless 
followed up with tissue expander and/or reconstruc-
tion), studies with less than 50 patients, and in-vivo/in-
vitro studies performed on cells and animals. See table, 
Supplemental Digital Content 1, which displays a list 
of indicators voted on across four Delphi rounds, and 
their voting outcomes, http://links.lww.com/PRSGO/
B167 for detailed search strategies and inclusion/exclu-
sion criteria. Figure 1 details a PRISMA flow diagram17 
summarizing the short-listing procedure and reasons for 
exclusion of articles.
We summarized the findings from studies on each can-
didate QI. Evidence assessment for each individual study 
was performed according to the National Health and 
Medical Research Council guidelines.18 Potential RAFs 
were also included in the consensus process.
Modified Delphi Process
Consensus on the final list of QIs and RAFs was 
achieved through a modified Delphi approach19 held over 
6 months (June–November 2017), which included online 
surveys and video teleconferences.
Delphi Expert Panel Selection
The expert panel was selected to represent a diverse 
range of experience with breast device surgery and 
breast device registries. A consumer representative was 
included to ensure the QIs aligned with patient values.20 
Invitations to participate were sent out to ICOBRA and 
ABDR collaborators who consented to take part in this 
project. The panel comprised 17 members, including 
elected representatives and practicing clinicians from 
surgical specialty groups. The panel comprised breast 
and general surgeons (E.E., C.S.), plastic and recon-
structive surgeons (R.D.C., H.R., M.Mur., B.S., N.D., 
A.D., H.K., M.Mag.), and cosmetic surgeons (R.B., M.H., 
C.M.), a breast-care nurse (J.B.), a consumer (C.S.-F.), a 
representative from the national regulator (P.C.) (Thera-
peutic Goods Administration, Australia) and a biostatis-
tician (A.E.). Countries with functioning breast device 
registries were represented (Australia, The Netherlands, 
and Sweden).
Statistical Analyses
Each candidate QI was rated for validity and feasibil-
ity as a measure of quality of breast device surgery on a 
six-point Likert scale, with 1 being least valid (or feasible) 
and 6 being most valid (or feasible). Validity, defined as 
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the ability of the indicator to capture the quality of breast 
device surgery, and feasibility defined as the ease of data 
collection for that candidate indicator.
Three statistical criteria were used for short-listing: 
(1) a median score of 5/6 or 1/2; (2) no disagreement 
(disagreement score of <1) according to the Interper-
centile Range Adjusted for Symmetry, calculated with the 
formula provided in the RAND Users’ Manual14; and (3) 
total of 70% or more panelists voting either 5/6 or 1/2.21 
A median of 5 or 6 was required for an indicator to be 
voted as valid or feasible and a median score of 1 or 2 was 
required for an indicator to be voted out as not valid or 
not feasible.
Opportunity to comment or suggest additional indica-
tors was included. Nonclinicians were given the option of 
responding “unsure” which was excluded from analysis. 
All data were deidentified, with results and comments pro-
vided to the panel before each teleconference, enabling 
comparison of individual responses with group responses. 
Indicators with disagreement were discussed during the 
Table 1. Candidate QIs
Number Quality Indicator Rationale Category
1 1a Intraoperative antibiotic wash 
(later changed to topical 
antibiotics)
Use of topical antibiotic wash (breast pocket irrigation and/or pocket 
wash) to reduce surgical infections.
Process
1b Intraoperative antiseptic wash 
(later changed to topical 
antiseptics)
Use of topical antiseptic wash (breast pocket irrigation and/or pocket 
wash) to reduce surgical infections.
2 Preoperative antibiotics Preoperative IV antibiotics provided before skin incision to reduce 
 complications postsurgery.
3 Nipple shields Use of nipple shields during surgery to reduce complications 
 postsurgery.
4 Drains Use of drains if clinically indicated.
5 Surgical plane For augmentation, the choice of surgical plane during surgery affects 
complications postsurgery.
6 Volume of implant The volume of the implant can affect complications postsurgery.
7 7a Funnels to reduce CC Use of funnel during surgery to reduce CC rates.
7b Funnels to reduce BIA- 
ALCL
Use of funnels during surgery to reduce the risk of BIA-ALCL.
8 8a Immediate versus delayed 
reconstruction
In reconstruction patients, immediate reconstruction with an implant 
is preferred over delayed reconstruction with an implant to reduce 
complications postsurgery.
8b Immediate versus delayed 
reconstruction with RT
Previous RT is known to increase the risk of complications after 
reconstruction: with this in mind, if RT is required, delayed implant 
based reconstruction is preferred over immediate implant based 
 reconstruction.
9 Time to revision (combined 
with reoperation in  
Round 2)
Time to reoperation (all cause). Outcome
10 10a Reoperation due to compli-
cations (augmentation) 
(combined with time to 
revision in Round 2)
Short-term reoperation rate (within 60 d of surgery) for augmentation 
due to: (1) infection; (2) capsular contracture; (3) device malposi-
tion/displacement; (4) device rupture/device deflation; (5) seroma/ 
hematoma; and (6) implant loss.
Long-term reoperation rate (after 60 d of surgery) for augmentation due 
to: (1) infection; (2) CC; (3) device malposition/displacement; (4) 
device rupture/device deflation rate; (5) seroma/hematoma; and (6) 
implant loss.
10b Reoperation due to compli-
cations (reconstruction) 
(combined with time to 
revision in Round 2)
Short-term reoperation rate (within 60 d of surgery) for reconstruction 
for: (1) infection; (2) CC; (3) device malposition/displacement; (4) 
device rupture/device deflation; (5) seroma/hematoma; and (6) 
implant loss.
Long-term reoperation rate (after 60 d of surgery) for reconstruction for: 
(1) infection; (2) CC; (3) device malposition/displacement; (4) device 
rupture/device deflation; (5) seroma/hematoma; (6) implant loss.
11 Patient satisfaction (later 
changed to patient 
reported outcome  
measures)
Patient satisfaction, when measured using validated patient-reported 
outcome measure.
12 Volume of activity Surgical volume in breast device surgery. Structure
BIA-ALCL, breast implant-associated anaplastic large cell lymphoma; RT, radiation therapy.
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teleconference. Each RAF was voted on its importance on 
a 6-point Likert scale.
All data analyses were performed on Microsoft Excel. 
Online surveys were administered using Qualtrics (Qual-
trics, Provo, Utah),22 and Zoom was used for teleconfer-
ences. The senior author (I.H.), a registry science expert 
who heads the Drug and Device Registries at Monash Uni-
versity, chaired the teleconferences.
RESULTS
Literature Review
The scoping literature search resulted in 4,395 ab-
stracts and 43 hand-searched articles. None of the gray 
literature was relevant. After removal of duplicates and 
screening based on eligibility criteria, 143 articles were 
summarized for the QIs with 8 articles of level IV evidence, 
111 articles of level III evidence, and 24 articles could not 
be assessed for level of evidence (review articles, or study 
type not stated). The majority of articles included in the 
literature review were for the outcome QIs. There were no 
articles found which related to three process QIs (nipple 
shields, funnels, volume of activity) based on our inclu-
sion/exclusion criteria.
For RAFs, 66 articles were short-listed with 50 articles 
of Level III evidence and 5 articles of Level II evidence. 
Eleven articles could not be assessed for level of evidence. 
There were 12 potential RAFs short-listed (see Table 2).
Delphi Process
There were 4 rounds of online survey and telecon-
ference. A summary of the voting results across all four 
modified Delphi rounds is provided in Supplementary 
Digital Content 1 for QIs and Supplementary Digital Con-
tent 2 for RAFs. Figure 2 shows the Delphi process and 
the level of participation during each round. (See table, 
Supplementary Digital Content 1, which displays a list of 
indicators voted on across four Delphi rounds, and their 
voting outcomes, http://links.lww.com/PRSGO/B167) 
(See table, Supplementary Digital Content 2, which dis-
plays a list of risk adjustment voted on across three Del-
Fig. 1. PriSMa flow diagram. *Full-text articles were excluded due to the following reasons: (1) articles 
had several study groups and size of study groups was less than 50 for augmentation and/or recon-
struction patients; (2) articles did not report data for individual comparison groups; and (3) articles fell 
under the exclusion criteria listed in the section above.
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phi rounds, and their voting outcomes, http://links.lww.
com/PRSGO/B168)
In the first round, 3 candidate QIs (intravenous an-
tibiotics, time to revision, and patient satisfaction), and 
subparts of 2 candidate QIs (intraoperative antibiotics 
and immediate versus delayed reconstruction with radio-
therapy) were voted in as being valid and feasible QIs. 
Teleconference discussion resulted in 2 outcome indica-
tors (time to revision, complications due to augmentation 
and reconstruction surgery) being combined into one 
(reoperation due to augmentation and reconstruction 
surgery). This new candidate QI included 6 complications 
as subcategories: infection, capsular contracture (CC), 
malposition/displacement, rupture/deflation, seroma/
hematoma, and implant loss. Intraoperative antibiotics/
antiseptics wash was changed to topical antibiotics/anti-
septics. Patient satisfaction was changed to Patient Report-
ed Outcome Measure (PROM).
In the second round, 3 QIs (topical antibiotics/anti-
septics, preoperative antibiotics, and PROM) were voted 
as being valid QIs. Reoperation due to complications 
was also voted in with the exception of the complication 
“short-term CC.” Eight RAFs (indication for surgery, age, 
body mass index, smoking, diabetes, acellular dermal ma-
trix/mesh, radiation therapy, and chemotherapy) were 
voted in as “important.” The panelists suggested 2 addi-
tional RAFs, immunosuppressive therapy and previous 
episode of fat grafting, which were added to the list of 
potential RAFs. During the teleconference, the issue of 
antimicrobial resistance was raised, and the panel mem-
bers requested a consultation with an infectious diseases 
expert before endorsing topical antibiotics and topical 
antiseptics as QIs.
In the third round, 7 candidate QIs were voted out 
(nipple shields, drains, surgical plane, funnels, immediate 
versus delayed reconstruction, and Surgical volume). One 
RAF (immunosuppressive therapy) was voted as important 
and 4 RAFs (ethnicity, hypertension, postmenopausal hor-
mone therapy, and previous fat grafting) were voted as not 
important and removed. Calculations (Figs. 3 and 4) for 
the QI “reoperation due to complications (infection, CC, 
malposition/displacement, rupture/deflation, seroma/
hematoma, and implant loss) within 60 days (short term) 
and after 60 days (long term) for both augmentation and 
reconstruction surgery” were discussed.
An external expert on infectious disease epidemiology 
(A.C.) participated in the Round 3 teleconference. There 
was consensus that topical antibiotics/antiseptics were not 
an appropriate QI currently, due to weak evidence sup-
porting it, in particular the lack of evidence from random-
ized control trials. Due to a low percentage of the panel 
members attending this teleconference, a second Round 
3 teleconference with the external infectious diseases ex-
pert present (A.C.) was held. It was agreed that topical 
antibiotics/antiseptics would not be a QI; however, these 
data would be collected by registries and reviewed again in 
light of accumulating evidence.
The fourth round resulted in topical antibiotics/an-
tiseptics (previously voted in by the Delphi panel in the 
second round), being voted out. Consensus on one RAF, 
large size of original breast, was not achieved in the final 
round, and was not included in the final list of RAFs.
After 4 rounds of survey and teleconferences, con-
sensus was achieved on 3 QIs (one process indicator and 
two outcome indicators, Table 3), and 9 RAFs (Table 4) 
for breast device surgery. The remaining indicators were 
deemed to require more data collection before they could 
be considered as potential QI, to be revisited in the future. 
No structural indicators were in the final list of endorsed 
QIs. It was agreed that data capture would be reviewed 
yearly, to monitor these endorsed QIs and feedback pro-
cessed data provided to participating local sites, with the 
aim of comparing data internationally across different 
breast device registries.
DISCUSSION
Following a scoping literature review, we used a Delphi 
process with a panel of 17 experts representing a broad 
range of views to reach consensus on 3 QIs and 9 RAFs 
for reporting on the quality of breast device surgery by 
Fig. 2. Panel participation in the 4 Delphi rounds.
Fig. 3. Method for calculating reoperation due to short-term com-
plication.
Fig. 4. Method for calculating reoperation due to long-term com-
plication. 
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CQRs. The QIs endorsed in this study are designed to use 
data from breast device CQRs for benchmarking quality 
of care. Other proposed QIs or RAFs were not endorsed 
at this stage, however, will be evaluated again in the fu-
ture. It is planned that they will be reviewed annually, and 
revised once every 3 years in light of new evidence.
Benchmarking using data from CQRs may occur at 
different levels, such as comparing the performance of 
different surgical techniques, different types of implants, 
at the surgeon or hospital level, and between countries. 
Identification of unwarranted variation and performance 
outliers has been shown to reduce variation over time, and 
lead to health care quality improvement.23 This work does 
not seek to replace more comprehensive assessments of 
outcomes of breast augmentation or reconstruction, such 
as BREAST-Q24; nor does it intend to substitute any exist-
ing guidelines for best practice, such as the guidelines for 
oncoplastic breast reconstruction.25,26
The endorsed QIs in this study include one process and 
2 outcome indicators. The selection of outcome measures 
for breast device surgery differs from quality measures in 
breast reconstruction surgery, which a recent systematic 
review27 demonstrated have an overrepresentation of pro-
cess measures to benchmark quality. Data in CQRs are col-
lected at a population level, thus providing the opportunity 
to systematically assess outcome measures. However, there 
are risks that should be considered if undertaking clinician 
level benchmarking, including low procedural volumes and 
the potential for clinician avoidance of high-risk patients.28
The Delphi panel endorsed only one process indicator, 
preoperative intravenous antibiotics. Despite the compara-
tive ease with which process measures are collected at the 
time of surgery, there is lack of quality data showing a di-




1a Process Topical antibiotics No
1b Topical antiseptics No
2 Preoperative IV antibiotics Yes
3 Nipple shields No
4 Drains No
5 Surgical plane No
6 Volume of implant No
7a Funnels to reduce CC No
7b Funnels to reduce BIA-ALCL No
8a Immediate versus delayed reconstruction No
8b Immediate versus delayed reconstruction with RT No
9 Outcome Reoperation due to complications Yes
























10 Patient reported outcome measure Yes
11 Structure Volume of surgical activity No
BIA-ALCL, breast implant-associated anaplastic large cell lymphoma; LT, long term; RT, radiation therapy; ST, short term.
Table 4. Outcomes of All Risk Adjustment Factors across 3 
Delphi Rounds
RAFs
Inclusion in  
Final Set of RAFs







Acellular dermal matrix/mesh Yes
Large size of original breast No
Postmenopausal hormone therapy No
Radiation therapy Yes
Chemotherapy Yes
Previous episode of fat grafting No
Immunosuppressive therapy Yes
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rect link with improved outcomes. Maxwell et al29 reported 
similar results, finding fewer items, such as drains, reaching 
consensus as a recommended practice which could then 
be used to measure quality. In our study, another process 
measure, topical antibiotics/antiseptics, was initially voted 
in. However, given the issue of antimicrobial resistance and 
the lack of high quality studies, the panel reconsidered its 
decision and decided against including it as a QI at this 
time. The panel also recognized the need for breast device 
registries to collect data on these potential process indica-
tors as more information becomes available.
The endorsement of outcome indicator PROMs as a QI 
reflects the importance of patient satisfaction as a measure 
of quality in this surgery, which is for the most part, elective. 
The International Consortium of Health Outcome Mea-
surement breast cancer set also recognizes the importance 
of PROMS in standardized health outcome measurement; 
however, it did not include breast device surgery specifi-
cally. The International Consortium of Health Outcome 
Measurement breast cancer set included the BREAST-Q, a 
validated PROM widely used in breast surgery.30 A 5 ques-
tion registry-specific version, the Breast-Q Implant Surveil-
lance, has been piloted as a PROM for use by breast device 
registries globally,31 and will be validated in due course.
The other outcome measure to be endorsed was reop-
eration due to complication. For this QI, the panel also 
agreed upon the method of calculating and reporting on 
reoperation, ensuring consistency in reporting of compli-
cation rates across breast device registries internationally. 
The one candidate structural measure in this study, vol-
ume of surgical activity, was not voted in as a QI due to 
lack of evidence linking volume of surgical throughput 
and surgical outcomes in breast device surgery. It is note-
worthy that this was also rejected by the Prostate Cancer 
Outcomes Registry (Australia),21 and has been called into 
question in other reports.32,33
Over half of the proposed RAFs reached consensus. 
These factors affect outcomes, and are beyond the control 
of the surgeon, therefore should be adjusted for in the sta-
tistical modeling used in benchmarking. Most RAFs were 
patient related (age, ethnicity, body mass index, and smok-
ing status) and linked to postoperative outcomes.34,35 Oth-
ers were specific to surgery and concomitant treatments 
(indication for surgery, radiation therapy, chemotherapy, 
and postmenopausal hormone therapy) that affect out-
comes. Most studies in our literature review reported 
results separately for cosmetic augmentation and breast 
reconstruction, and it is clear that these groups should be 
considered separately for benchmarking.
The modified Delphi approach has been used widely 
in health research. Examples include selection of QI for 
hospital-based emergency care,36 and cancer care such as 
prostate, colorectal, ovarian, and breast cancers.37–41 Simi-
lar studies performed for breast implants have utilized a 
modified Delphi approach without the literature reviews29 
or have focused only on breast reconstruction.27,42,43 This 
is the first study identifying potential QIs for breast de-
vice CQRs for both cosmetic augmentation and breast 
reconstruction purposes. Additionally, it encompasses 
both detailed scoping literature reviews and inputs from 
an international multidisciplinary panel of experts includ-
ing all surgical implanters: plastic and reconstructive sur-
geons, breast and general surgeons, and cosmetic surgeon 
groups.
The strengths of this process include the four round 
modified Delphi process in combination with stringent 
statistical criteria. We used 3 statistical measures instead of 
the usual 221 to ensure a clear consensus on the key indi-
cators, reflected in the fact that a consensus was reached 
for all the proposed QIs and all but one of the RAFs. Fur-
thermore, all comments from panelists across the 4 voting 
rounds were addressed in the teleconference discussion, 
robust discussions took place in which rephrasing of the 
proposed QIs, as well as the addition of complications, 
and risk factors were incorporated.
Most registries already collect data on the QIs that 
have been voted in this study. The ICOBRA group has 
also established a global minimum dataset for all registries 
to collect, which includes Preoperative antibiotics and 
Complications. Additionally, PROMs are currently being 
collected by the Australian31 and Swedish registries,4 with 
others planning to follow.
The Delphi panel in our study comprised 17 members 
which, according to a systematic review including 80 stud-
ies selecting healthcare quality indicators,19 is the median 
number of individuals invited to participate in the Delphi 
panels. The review did not have any specific recommenda-
tions for the size of a Delphi panel, but suggested that a 
Delphi panel that reflects the full range of stakeholders 
enhances the credibility and acceptance of QIs. Our study 
involved diverse representatives with expertise in breast 
device surgery and importantly, from currently function-
ing breast device registries, taking the consumer and regu-
latory perspectives into account, and was independent of 
industry.
The limitations of this study were a scoping review 
rather than a comprehensive systematic review was per-
formed, although care was taken to include all relevant 
articles based on hand searching of literature. Second, in-
dicators were limited to process, outcome and structural 
measures of care, and preoperative assessment factors, 
such as patient anatomy, were not included in this study. 
Finally, video conferencing facilities were used for the 
teleconferences, which may have caused potential bias, as 
the discussions are not anonymous. However, the results 
of the online surveys were anonymized during the tele-
conference discussions and the moderator (I.H.) ensured 
that no one person influenced the views of the entire 
group and encouraged comments from all present. Panel-
ists were also given a chance to write in their views over 
chat during the teleconference or speak to the moderator 
separately after the teleconference sessions.
CONCLUSIONS
With the use of a combination of a comprehensive 
scoping review process and expert input from a panel of 
clinicians and others, we identified a set of 3 clinical QIs 
and 9 RAFs for use by breast device CQRs. The 3 endorsed 
quality indicator measures will enable breast device regis-
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tries to benchmark care internationally for patients under-
going breast device surgery. Uniform reporting practices 
enable registries to ensure continual safety and consisten-
cy in the quality of care and improvement in patient out-
comes. These indicators will be continually evaluated and 
refined to reflect new data made available from registries 
and other large-scale studies.
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